Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 28;18(1):177.
doi: 10.1186/s12876-018-0906-8.

Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study

Affiliations

Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study

Francesco Giuseppe Foschi et al. BMC Gastroenterol. .

Abstract

Background: The estimation of the burden of disease attributable to fatty liver requires studies performed in the general population.

Methods: The Bagnacavallo Study was performed between October 2005 and March 2009. All the citizens of Bagnacavallo (Ravenna, Italy) aged 30 to 60 years as of January 2005 were eligible. Altered liver enzymes were defined as alanine transaminase > 40 U/l and/or aspartate transaminase > 37 U/l.

Results: Four thousand and thirty-three (58%) out of 6920 eligible citizens agreed to participate and 3933 (98%) had complete data. 393 (10%) of the latter had altered liver enzymes and 3540 had not. After exclusion of subjects with HBV or HCV infection, liver ultrasonography was available for 93% of subjects with altered liber enzymes and 52% of those with normal liver enzymes. The prevalence of fatty liver, non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) was 0.74 (95%CI 0.70 to 0.79) vs. 0.35 (0.33 to 0.37), 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) and 0.28 (0.24 to 0.33) vs. 0.13 (0.11 to 0.14) in citizens with than in those without altered liver enzymes. Ethanol intake was not associated and all the components of the metabolic syndrome (MS) were associated with fatty liver. All potential risk factors were associated with a lower odds of normal liver vs. NAFLD while they were unable to discriminate AFLD from NAFLD.

Conclusions: Fatty liver as a whole was highly prevalent in Bagnacavallo in 2005/9 and was more common among citizens with altered liver enzymes.

Keywords: chronic liver disease; cross-sectional study; epidemiology; fatty liver; prevalence; risk factors.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the Ethical Committee of Area Vasta Romagna - IRST (reference number 112). All citizens gave written informed consent.

Consent for publication

Not applicable.

Competing interests

Stefano Bellantani is an Editorial Board Member for BMC Gastroenterology.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow of the subjects through the study. Abbreviations: ALE = altered liver enzymes; HBV = Hepatitis B virus; HCV = hepatitis C virus; LUS = liver ultrasonography; FL = fatty liver
Fig. 2
Fig. 2
Prevalence of fatty liver in men and women with and without altered liver enzymes as estimated by Model 3 of Table 2. Values are proportions and pointwise 95% confidence intervals. Abbreviations: ALE = altered liver enzymes; FL = fatty liver; BMI = body mass index. The values of age correspond to the 5th (34 yr), 25th (41 yr), 50th (49 yr), 75th (56 yr) and 95th (61 yr) internal percentiles. The values of BMI correspond to the 5th (19.7 kg/m2), 25th (23.0 kg/m2), 50th (25.5 kg/m2), 75th (28.9 kg/m2) and 95th (35.1 kg/m2) internal percentiles and alcohol intake is set to the median value

References

    1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. doi: 10.1002/hep.29367. - DOI - PubMed
    1. EASL-EASD-EASO EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402. - PubMed
    1. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117. doi: 10.7326/0003-4819-132-2-200001180-00004. - DOI - PubMed
    1. Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340:c1240. doi: 10.1136/bmj.c1240. - DOI - PMC - PubMed
    1. Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: an update. World J Gastroenterol. 2014;20:9050–9054. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources